Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer?

CONCLUSIONS: This model could be a helpful tool for the surgeon to help in predicting which cases have a higher likelihood of achieving a pathologically complete response and therefore selecting those who may benefit from a post-neoadjuvant chemotherapy sentinel lymph node biopsy and avoid unnecessary axillary lymphadenectomy. PMID: 30421628 [PubMed - as supplied by publisher]
Source: Annals of the Royal College of Surgeons of England - Category: Surgery Authors: Tags: Ann R Coll Surg Engl Source Type: research

Related Links:

CONCLUSIONS: HER2Bi- or EGFRBi-armed CART19 exhibited specific cytotoxicity against multiple HER2+/EGFR+/CD19- tumor targets in overnight and long-term serial killing assays. CART19 showed improved survival and were resistant to exhaustion after prolonged repeated exposure to tumor cells. PMID: 32449004 [PubMed - indexed for MEDLINE]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
This article explores and reports on the data used to make this policy amendment. PMID: 32657737 [PubMed - as supplied by publisher]
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
Pesantez Maria Vidal Barbara Adamo Montserrat Muñoz Patricia Galván Laura Barberá Miriam Cuatrecasas Mathias Christgen Hans Kreipe Inés Monge-Escartín Patricia Villagrasa Dolors Soy Tommaso Giarratano Maria Vittoria Dieci Pierfranco Conte Nadia Harbeck Valentina Guarneri Aleix Prat Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that t...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusion: In large high-quality data, BB use at the time of anti-HER2 therapy initiation for ABC was independently associated with worse OS, regardless of CVD status. The finding is contrary to pre-study hypotheses and findings in other BC subtypes. Future research should aim to gain a deeper understanding of the effects of BBs on specific BC subtypes, cancer types, and cancer treatments.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   HER2 Positive Breast Cancer Intervention:   Drug: AIP-303 Sponsors:   Advanced Imaging Projects, LLC;   All India Institute of Medical Sciences, New Delhi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: Patient age has a significant influence if elderly patients with axillary disease receive radiotherapy. Further investigation and validation are needed to understand why chronological age rather than biological age influences treatment modalities.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
HER2 dual-blockade combined with aromatase inhibitors (AI) is a promising strategy to improve progression-free survival (PFS) in hormone receptor (HR) positive, metastatic breast cancer (MBC). Pyrotinib is a n...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Study protocol Source Type: research
SummaryAt the 2019 San Antonio Breast Cancer Symposium, new data on the management of heavily pretreated human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer were discussed. The phase  3 HER2CLIMB and the phase 2 DESTINY-Breast01 trials investigating tucatinib and trastuzumab deruxtecan, respectively, have met their primary endpoints.In an early disease setting, four studies investigated whether image-guided biopsies could identify patients with a  pathologic complete response (pCR) to neoadjuvant chemotherapy, thus allowing safe omission of surgery. As residual disease was m...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Modern Pathology, Published online: 13 July 2020; doi:10.1038/s41379-020-0620-2Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study
Source: Modern Pathology - Category: Pathology Authors: Source Type: research
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.0c07353
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
More News: Breast Cancer | Breast Needle Aspiration | Breast Surgery | Cancer | Cancer & Oncology | Chemotherapy | Cytology | Fine Needle Aspiration | HER2 | MRI Scan | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Royal College of Surgeons | Study | Surgery | Ultrasound